NeurAxis, Inc. (NYSE American: NRXS) is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions affecting children and adults. The company’s proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology is designed to address functional gastrointestinal disorders, including pediatric irritable bowel syndrome (IBS), functional abdominal pain, and related conditions where treatment options remain limited.

Topics discussed include the company’s commercial strategy, technology platform, clinical initiatives, market opportunities, and the expansion of neuromodulation therapies across additional patient populations.

This company webcast was recorded during the Lytham Partners Spring 2026 Investor Conference